7027 Interim results of a phase II trial of oxaliplatin and pemetrexed as 2nd/3rd line therapy in castration resistant prostate cancer (CRPC)T. B. Dorff,S. Groshen,D. D. Tsao-Wei,A. Goldkorn,C. Korn,D. I. Quinn,J. PinskiEJC SUPPLEMENTS（2009）引用 0|浏览19暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
